VNDA (Vanda Pharmaceuticals) Other Current Payables: $43.4 Mil (As of Mar. 2026)


VNDA Vanda Pharmaceuticals Inc VNDA
71 GF Score
Price $6.50
GF Value $5.52
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Other Current Payables?

Vanda Pharmaceuticals VNDA +1.72% 71 Other Current Payables is $43.4 Mil as of Mar. 2026. GuruFocus rates VNDA with a GF Score™ of 71/100 and a GF Value™ of $5.52 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Vanda Pharmaceuticals's Other Current Payables for the quarter that ended in Mar. 2026 was $43.4 Mil.

Vanda Pharmaceuticals's quarterly Other Current Payables increased from Sep. 2025 ($31.0 Mil) to Dec. 2025 ($37.5 Mil) and increased from Dec. 2025 ($37.5 Mil) to Mar. 2026 ($43.4 Mil).

Vanda Pharmaceuticals's annual Other Current Payables increased from Dec. 2023 ($22.5 Mil) to Dec. 2024 ($22.9 Mil) and increased from Dec. 2024 ($22.9 Mil) to Dec. 2025 ($37.5 Mil).

Vanda Pharmaceuticals Other Current Payables Related Terms

Vanda Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Other Current Payables Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.69 23.69 22.50 22.85 37.48

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.10 43.36 31.04 37.48 43.44
VNDA
71GF Score
Vanda Pharmaceuticals Inc VNDA
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $43.4 Mil mean?
Vanda Pharmaceuticals (VNDA) has a Other Current Payables of $43.4 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Other Current Payables too high?
Vanda Pharmaceuticals' current Other Current Payables is $43.4 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Other Current Payables compare to AVIR and OABI?
Vanda Pharmaceuticals' Other Current Payables of $43.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Other Current Payables is $43.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.52, compared to a current price of $6.50 — trading 17.8% above its estimated fair value. The current Other Current Payables is $43.4 Mil. Vanda Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Other Current Payables is $43.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of $6.50 is trading 17.8% above its estimated GF Value™ of $5.52. GuruFocus considers Vanda Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for VNDA:

  • Other Current Payables: $43.4 Mil
  • GF Value™: $5.52 vs. price of $6.50 (17.8% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges 0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
71GF Score

Get the complete analysis for VNDA

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.50
Price
$5.52
GF Value